Cartalax Peptide: What the Research Shows, and What It Doesn’t

Cartalax is a peptide chain of only three amino acids: alanine, glutamic acid and aspartic acid, abbreviated AED. Few peptides on the market are smaller, and it is sold mostly on joint and cartilage claims.
Most of what you will read about it online goes far beyond the facts. Here is what Cartalax is, every study we could find on it, what those studies did not show, and how it relates to the other bioregulators.
Three amino acids from a cartilage extract
Cartalax is H-Ala-Glu-Asp-OH, molecular weight about 333. It was developed in the laboratory of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, which worked for decades on short peptides it calls bioregulators. Some of the group’s early papers refer to it by the lab code T-31.
According to Khavinson, AED was first identified by mass spectrometry in Chondrolux, a peptide preparation made from cartilage. His team later synthesized it and patented it in Russia for “normalizing metabolism in bone and cartilage tissue.” That patent is where the cartilage label comes from.
One thing to watch for: some sites list Cartalax as Ala-Glu-Asp-Gly. That four-amino-acid sequence, AEDG, is Epitalon, a different peptide.
Two products share the name
“Cartalax” can mean two different things, and they are easy to confuse.
| Research peptide | Cartalax capsules | |
|---|---|---|
| What it is | Synthetic AED, freeze-dried in a vial | Oral supplement sold in Russia |
| Form | Powder for reconstitution | Capsules and tablets |
| Status | Research use only | Listed in Russia as a dietary supplement |
There is one more Canadian angle. Health Canada’s natural health products database lists a product called CARTALAX, licence number 80041188, issued in 2013. It is an oral capsule containing “glutamine peptides” at 100 mcg, and its only permitted claim is that it provides amino acids for protein synthesis. It makes no cartilage claim and doesn’t mention AED. It is not an approval of the research peptide.
The research, study by study
Every study below is from Khavinson’s group or its collaborators. None has been repeated by an independent lab that we could find.
| Year | Model | What changed | PMID |
|---|---|---|---|
| 2007 | Rats with ovaries removed | Bone mineral density partly protected, less than with the cartilage extract | 18306703 |
| 2014 | Ageing kidney cells | More cell division (Ki-67), less p53 | 24958378 |
| 2015 | Rat kidney tissue | More cell division, less cell death | 26033601 |
| 2016 | Ageing skin fibroblasts | Lower MMP-9 and caspase-3, higher Ki-67 | 27259496 |
| 2020 | Skin fibroblasts | Higher SIRT1, SIRT6 and type I collagen | 33231794 |
| 2023 | Ageing human stem cells (MSCs) | Higher SOX9, aggrecan and type II collagen, the cartilage markers | 37782646 |
| 2023 | Ageing chondrocytes | Ageing and inflammation markers (p16, p21, p53, TNF-α) moved back toward normal | 37356100 |
If you see Cartalax described as “activating cartilage genes,” the 2023 stem cell study is the closest match. The cells were mesenchymal stem cells, not cartilage cells, and the paper is in Russian, in the journal Advances in Gerontology.
What the research has not shown
- No human trial. No peer-reviewed human study of Cartalax is indexed in PubMed. The only human data is in the Russian patent: 29 people with knee osteoarthritis and 12 controls, reported by the patent holders themselves.
- No proven mechanism. Khavinson’s theory is that short peptides enter the cell nucleus and bind DNA. For AED, the support is computer docking models plus gene-expression changes. No paper we found shows AED binding DNA inside a cell.
- No published dose. There is no human dose in the peer-reviewed literature. Online “protocols” such as 10 mg for 10 days have no source behind them.
- No approval. Cartalax is not approved by the FDA, and the research peptide has no drug identification number in Canada.
The bioregulator family
Khavinson’s team matched each of these short peptides to the tissue extract it came from. These are the ones we carry, with the target tissue their own papers list:
| Peptide | Sequence | Linked to | Vial |
|---|---|---|---|
| Cartalax | AED | Cartilage and bone | 20 mg, $60 |
| Epithalon | AEDG | Pineal gland | 10 mg, $30 |
| Pinealon | EDR | Brain | 20 mg, $55 |
| Cortagen | AEDP | Brain | 20 mg, $55 |
| Vilon | KE | Immune system (thymus) | 20 mg, $55 |
| Livagen | KEDA | Liver | 20 mg, $55 |
| Cardiogen | AEDR | Heart | 20 mg, $55 |
| Testagen | KEDG | Male reproductive system | 20 mg, $60 |
Notice how many share the same A-E-D core. Epitalon is Cartalax plus glycine; Cardiogen is Cartalax plus arginine. Our Pinealon profile covers the brain side of the family.
Preparing a 20 mg vial
Cartalax ships as a dry powder. Reconstituted in 2 mL of bacteriostatic water ($10), the 20 mg vial works out to 10 mg per mL. A U-100 syringe marks 0.01 mL per unit, so one unit carries 100 mcg and 10 units carry 1 mg.
Run the water down the side of the vial, swirl rather than shake, and keep it refrigerated once mixed. Our reconstitution guide walks through each step, and aliquoting helps if a vial will last a while.
Quick answers
What is Cartalax?
A three-amino-acid peptide, Ala-Glu-Asp, developed by Khavinson’s group and linked to cartilage tissue.
Does Cartalax regrow cartilage?
That has not been shown. The cartilage findings are from cell cultures, mostly stem cells, plus unpublished patent data.
Is Cartalax the same as Epitalon?
No. Epitalon is AEDG, four amino acids. Cartalax is AED.
Is Cartalax FDA approved?
No.
Cartalax is a research compound, not approved for use in people, and this page is not medical advice. Study details are from PubMed (PMIDs above), Molecules 2021 (PMID 34834147), Int J Mol Sci 2022 (PMID 35887081), Russian patent RU2299741 and Health Canada’s Licensed Natural Health Products Database. Prices in USD, current October 2026.